C12N 2799/022
Where the vector is derived from an adenovirus
Official title: where the vector is derived from an adenovirus
C12N2799/022 (Where the vector is derived from an adenovirus) appears on 478 US grants and 698 published applications in this corpus.
Search patents in C12N- Granted patents
- 478
- Published applications
- 698
- Assignees
- 334
- Inventors
- 1,203
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 14 | 0 |
| 1999 | 14 | 0 |
| 2000 | 24 | 0 |
| 2001 | 23 | 9 |
| 2002 | 32 | 55 |
| 2003 | 23 | 100 |
| 2004 | 29 | 74 |
| 2005 | 27 | 57 |
| 2006 | 19 | 34 |
| 2007 | 18 | 47 |
| 2008 | 24 | 47 |
| 2009 | 27 | 46 |
| 2010 | 30 | 34 |
| 2011 | 29 | 42 |
| 2012 | 27 | 25 |
| 2013 | 15 | 26 |
| 2014 | 14 | 20 |
| 2015 | 11 | 12 |
| 2016 | 15 | 19 |
| 2017 | 11 | 13 |
| 2018 | 9 | 4 |
| 2019 | 7 | 10 |
| 2020 | 4 | 9 |
| 2021 | 8 | 4 |
| 2022 | 2 | 4 |
| 2023 | 2 | 1 |
| 2024 | 4 | 5 |
| 2025 | 3 | 1 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions for use in treating autosomal dominant BEST1-related retinopathies31 Mar 2026US 12,590,323 B2UniversitäT Regensburg
- Gene therapy for ocular disorders2 Sep 2025US 12,403,204 B2The Trustees of the University of Pennsylvania
- Composition comprising NC886 for improving oncolytic virus activity or production26 Aug 2025US 12,398,376 B2National Cancer Center
- Targeted neoepitope vectors and methods therefor27 May 2025US 12,311,018 B2NantCell, Inc.
- Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditions15 Oct 2024US 12,116,577 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Methods and related aspects for increasing antigenic insertion sites on a recombinant immune complex platform17 Jul 2025US 2025/0228925 A1Arizona Board of Regents on behalf of Arizona State University
- Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions12 Dec 2024US 2024/0409948 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Tumor-targeting synthetic adenoviruses and uses thereof27 Jun 2024US 2024/0207445 A1The Salk Institute for Biological Studies
- Biomarkers of aging for detection and treatment of disorders13 Jun 2024US 2024/0191238 A1The Board of Trustees of the Leland Stanford Junior University
- Synergistic Genome-Nonintegrating Reprogramming by Micrornas and Transcription Factors25 Apr 2024US 2024/0132852 A1The McLean Hospital Corporation
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Polypeptide variants with altered effector function381US 7,371,826 B2Genentech, Inc. · 2008
- Polypeptide variants with altered effector function373US 7,332,581 B2Genentech, Inc. · 2008
- Spray drying of macromolecules to produce inhaleable dry powders220US 6,582,728 B1Inhale Therapeutic Systems · 2003
- Pericardial delivery of therapeutic and diagnostic agents189US 5,797,870 AIndiana University Foundation · 1998